About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

25.36 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Viking Therapeutics Q3 Earnings Call Highlights ↗
Viking Therapeutics (NASDAQ:VKTX) reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of... 
Via MarketBeat
Topics Earnings
News headline image
Viking (VKTX) Q3 2026 Earnings Call Transcript ↗
VK2735 obesity drug shows up to 22% weight loss with less frequent dosing schedules. 
Via The Motley Fool
Topics Earnings
Viking Therapeutics (NASDAQ:VKTX) Q3 2026 Earnings: Wider Loss as Obesity Pipeline Advances ↗
Via Chartmill
News headline image
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years ↗
Viking Therapeutics has a lot riding on its leading pipeline candidate. 
Via The Motley Fool
News headline image
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2 ↗
Nothing is certain in clinical trials, but investors have reason to expect a better outcome in the oral VK2735 trials. 
Via The Motley Fool
News headline image
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735. 
Via The Motley Fool
News headline image
4 High-Risk Stocks Built for Big Returns ↗
These speculative investments could turbocharge a portfolio to market-beating returns. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Absurdly Cheap Stocks to Buy Before the End of 2026 ↗
These stocks are priced incredibly low and possess significant upside. 
Via The Motley Fool
News headline image
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. ↗
Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug. 
Via The Motley Fool
News headline image
2 Stocks That Could Soar in Q4 ↗
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines. 
Via The Motley Fool
News headline image
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? ↗
Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start. 
Via The Motley Fool
News headline image
Here Are My Top 4 Stocks to Buy in October ↗
Get 'em while they're still on sale. Catalysts are on the horizon. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? ↗
The weight loss drug company continues to make progress, but its share price is bouncing around with events. 
Via The Motley Fool
News headline image
Prediction: This Stock Could Double Over the Next 5 Years ↗
The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock. 
Via The Motley Fool
News headline image
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗
Could this be what Novo needs to turn things around? 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. ↗
There could be more catalysts for the biotech over the next 18 months. 
Via The Motley Fool
News headline image
3 Emerging Biotech Stocks With Significant Upside Potential ↗
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs. 
Via MarketBeat
Topics Intellectual Property
News headline image
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. ↗
Both stocks may be worth considering for those looking to capitalize on the anti-obesity market. 
Via The Motley Fool
News headline image
3 Non-AI Growth Stocks That Have Massive Upside ↗
Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? ↗
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug. 
Via The Motley Fool
News headline image
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution ↗
The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial. 
Via The Motley Fool
News headline image
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing ↗
The company continues to make good progress with its key obesity treatment drug, VK2735. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 09/21 - 09/25 ↗
A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm. 
Via MarketBeat
Topics Artificial Intelligence Bonds Economy
News headline image
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗
The biotech player could eventually rival big pharma companies. 
Via The Motley Fool
News headline image
Here's Why Viking Therapeutics Shares Slumped Today ↗
It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about. 
Via The Motley Fool
News headline image
Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved. 
Via MarketBeat
News headline image
Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off. 
Via The Motley Fool
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.